Chemotherapy alters radiosensitivity and GRPR expression of prostate and breast cancer cells [PDF]
EJNMMI ResearchBackground Gastrin releasing peptide receptor (GRPR)-targeting radiotracers have been studied (pre)-clinically with promising results. Patients eligible for this treatment are likely to have undergone prior treatments with other anti-cancer agents ...
Simone Dalm, Corrina de Ridder
exaly +3 more sources
Bioorthogonal Chemistry Approach for the Theranostics of GRPR-Expressing Cancers
Pharmaceutics, 2022 Several gastrin-releasing peptide receptor (GRPR) antagonists with improved in vivo behavior have been recently developed and tested in the clinic. However, despite the generally mild side effects of peptide receptor radionuclide therapy (PRRT), toxicity
Alice D'Onofrio +2 more
exaly +3 more sources
The gastrin-releasing peptide receptor as a potential biomarker for squamous cell carcinoma [PDF]
Scientific ReportsThe gastrin-releasing peptide receptor (GRPR) is expressed across multiple human cancer types, including head and neck tumors, and has also been detected in the oral mucosa of patients bearing head and neck neoplasms.
Danielly Brufatto Olguins +9 more
doaj +2 more sources
The gastrin-releasing peptide receptor in oncology: a comprehensive review of recent advances in targeted radionuclide theranostics [PDF]
Frontiers in OncologyThe gastrin-releasing peptide receptor (GRPR) is aberrantly expressed in several malignancies, including prostate cancer, breast cancer, lung cancer, and gastrointestinal stromal tumors, making it an important target for molecular imaging and targeted ...
YunLong Yang +18 more
doaj +2 more sources
GRPR Drives Metastasis via CRABP2 and FNDC4 Pathways in Lung Adenocarcinoma
CellsMetastasis is a leading cause of lung adenocarcinoma (LUAD)-related mortality and presents significant challenges for treatment. The gastrin-releasing peptide receptor (GRPR), a member of the G protein-coupled receptor (GPCR) family, has an unclear role ...
Dong-Gun Kim
exaly +3 more sources
Pharmaceutics, 2020 Prostate-specific membrane antigen (PSMA) and gastrin-releasing peptide receptor (GRPR) are promising targets for molecular imaging of prostate cancer (PCa) lesions.
Anna Orlova, Mats Larhed, Bogdan Mitran
exaly +3 more sources
Gastrin-releasing peptide signaling in the nucleus accumbens medial shell regulates neuronal excitability and motivation [PDF]
Nature CommunicationsNeuropeptides are the largest class of neuromodulators. It has been shown that subpopulations of ventral tegmental area (VTA) dopamine neurons express mRNA for the neuropeptide Gastrin-releasing peptide (GRP); however, its functional relevance in ...
Erin E. Aisenberg +5 more
doaj +2 more sources
GRPR-targeting radiotheranostics for breast cancer management
Frontiers in Medicine, 2023 Breast Cancer (BC) is the most common cancer worldwide and, despite the advancements made toward early diagnosis and novel treatments, there is an urgent need to reduce its mortality.
Axel Rominger +2 more
exaly +3 more sources
Annals of MedicineAim: This comprehensive review aims to explore the potential applications of Gastrin-releasing peptide receptor (GRPR) in the diagnosis and treatment of prostate cancer.
Yi Cai
exaly +3 more sources
Improving GRPR-targeting peptides for radiotheranostics application: insights from chelator modifications and α-methyl-L tryptophan substitution [PDF]
EJNMMI Radiopharmacy and ChemistryBackground Targeting the gastrin-releasing peptide receptor (GRPR) is a promising approach for radionuclide therapy in prostate and breast cancers.
Karim Obeid +4 more
doaj +2 more sources